Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc): protocol for a group randomised controlled trial of a novel intervention addressing cognitions
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Severe hypoglycaemia (SH), when blood glucose falls too low to support brain function, is the most feared acute complication of insulin therapy for type 1 diabetes mellitus (T1DM). 10% of people with T1DM contribute nearly 70% of all episodes, with impaired awareness of hypoglycaemia (IAH) a major risk factor. People with IAH may be refractory to conventional approaches to reduce SH, with evidence for cognitive barriers to hypoglycaemia avoidance. This paper describes the protocol for the Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc) study, a trial to assess the impact on hypoglycaemia experience of a novel intervention that addresses cognitive barriers to hypoglycaemia avoidance, compared with an existing control intervention, recommended by the National Institute of Health and Care Excellence. Methods and analysis: A randomised parallel two-arm trial of two group therapies: HARPdoc versus Blood Glucose Awareness Training, among 96 adults with T1DM and problematic hypoglycaemia, despite attendance at education with or without technology use, in four centres providing specialist T1DM services. The primary outcome will be the SH rate at 12 and/or 24 months after randomisation to either course. Secondary outcomes include rates of SH requiring parenteral therapy, involving unconsciousness or needing emergency services; hypoglycaemia awareness status, overall diabetes control and quality of life measures. An implementation study to evaluate how the interventions are delivered and how implementation impacts on clinical effectiveness is planned as a parallel study, with its own protocol. Ethics and dissemination: The protocol was approved by the London Dulwich Research Ethics Committee, the Health Research Authority, National Health Service R&D and the Institutional Review Board of the Joslin Diabetes Center in the USA. Study findings will be disseminated to study participants and through peer-reviewed publications and conference presentations, including user groups. Trial registration number: NCY02940873; Pre-results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curran, G. M., Bauer, M., Mittman, B., Pyne, J. M., & Stetler, C. (2012) · Medical Care · doi:10.1097/mlr.0b013e3182408812 · Cited by 4,058 · cited 1×
“In carrying out a parallel evaluation of clinical and implementation endpoints and in correlating the two sets of endpoints as part of the overall trial, we are conducting what has recently been termed a ‘hybrid effectiveness-implementation type II’ study.(60) The implementation study has a study protocol, coauthored…”
MethodNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Assessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Self-citationInternational Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Mitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 1×
“People with T1DM have defects in endogenous counter-regulatory mechanisms that maintain plasma glucose.(13) 14 Their best protection against SH is subjective awareness of the start of a plasma glucose fall, driving ingestion of rapidly absorbed carbohydrate.”
BackgroundWild, D., von Maltzahn, R., Brohan, E., Christensen, T., Clauson, P., & Gonder-Frederick, L. (2007) · Patient Education and Counseling · doi:10.1016/j.pec.2007.05.003 · Cited by 545
Self-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citationHeinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Bolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.
Amiel, S. A., Sherwin, R. S., Simonson, D. C., & Tamborlane, W. V. (1988) · Diabetes · doi:10.2337/diab.37.7.901 · Cited by 393
Self-citationLong-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway
Skrivarhaug, T., Bangstad, H.-J., Stene, L. C., Sandvik, L., Hanssen, K. F., & Joner, G. (2006) · Diabetologia · doi:10.1007/s00125-005-0082-6 · Cited by 390
Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes
Geddes, J., Schopman, J. E., Zammitt, N. N., & Frier, B. M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02413.x · Cited by 387
Huxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383
Pedersen‐Bjergaard, U., Pramming, S., Heller, S. R., Wallace, T. M., Rasmussen, Å. K., Jørgensen, H. V., Matthews, D. R., Hougaard, P., & Thorsteinsson, B. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.482 · Cited by 371
Self-citationPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337
Self-citationHopkins, D., Lawrence, I., Mansell, P., Thompson, G., Amiel, S., Campbell, M., & Heller, S. (2012) · Diabetes Care · doi:10.2337/dc11-1579 · Cited by 265
Self-citationReddy, M., Jugnee, N., El Laboudi, A., Spanudakis, E., Anantharaja, S., & Oliver, N. (2018) · Diabetic Medicine · doi:10.1111/dme.13561 · Cited by 245 · cited 1×
“However, there are no data on the impact of CSII on IAH, and use of real-time CGM does not restore IAH, making patients dependent on the technology longterm.(34) Guidelines suggest a stepwise approach through education and technology, but some people continue to report IAH and SH(16); some cannot engage successfully w…”
BackgroundLittle, S. A., Leelarathna, L., Walkinshaw, E., Tan, H. K., Chapple, O., Lubina-Solomon, A., Chadwick, T. J., Barendse, S., Stocken, D. D., Brennand, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0030 · Cited by 237
Self-citationBlood Glucose Awareness Training (BGAT-2)
Cox, D. J., Gonder-Frederick, L., Polonsky, W., Schlundt, D., Kovatchev, B., & Clarke, W. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.637 · Cited by 235
Self-citationPatterson, C. C., Dahlquist, G., Harjutsalo, V., Joner, G., Feltbower, R. G., Svensson, J., Schober, E., Gyürüs, E., Castell, C., Urbonaité, B., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0824-8 · Cited by 213
Feltbower, R. G., Bodansky, H. J., Patterson, C. C., Parslow, R. C., Stephenson, C. R., Reynolds, C., & McKinney, P. A. (2008) · Diabetes Care · doi:10.2337/dc07-2029 · Cited by 183
Yeoh, E., Choudhary, P., Nwokolo, M., Ayis, S., & Amiel, S. A. (2015) · Diabetes Care · doi:10.2337/dc15-0102 · Cited by 154
Self-citationElliott, J., Jacques, R. M., Kruger, J., Campbell, M. J., Amiel, S. A., Mansell, P., Speight, J., Brennan, A., & Heller, S. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12441 · Cited by 112 · cited 1×
“The UK’s National Institute for Health and Clinical Excellence (NICE) recommended BGAT for T1DM adults with problematic hypoglycaemia,(44) although BGAT is not currently offered in the UK and has not formally been tested in people who have already completed structured education in flexible intensive insulin therapy as…”
BackgroundSelf-citationSmith, C. B., Choudhary, P., Pernet, A., Hopkins, D., & Amiel, S. A. (2009) · Diabetes Care · doi:10.2337/dc08-2259 · Cited by 106
Self-citationSpeight, J., Barendse, S. M., Singh, H., Little, S. A., Inkster, B., Frier, B. M., Heller, S. R., Rutter, M. K., & Shaw, J. A. M. (2016) · Diabetic Medicine · doi:10.1111/dme.12824 · Cited by 76
Self-citationSchachinger, H., Hegar, K., Hermanns, N., Straumann, M., Keller, U., Fehm-Wolfsdorf, G., Berger, W., & Cox, D. (2005) · Journal of Behavioral Medicine · doi:10.1007/s10865-005-9026-3 · Cited by 73
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Amiel, S. A., Potts, L., Goldsmith, K., Jacob, P., Smith, E. L., Gonder-Frederick, L., Heller, S., Toschi, E., Brooks, A., Kariyawasam, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29488-x · Cited by 61
Self-citation
Metadata
- Authors
- Amiel, S. A., Choudhary, P., Jacob, P., Smith, E. L., De Zoysa, N., Gonder-Frederick, L., Kendall, M., Heller, S., Brooks, A., Toschi, E., Kariyawasam, D., Potts, L., Healy, A., Rogers, H., Sevdalis, N., Stadler, M., Qayyum, M., Bakolis, I., & Goldsmith, K.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-06
- Volume
- 9
- Issue
- 6
- Pages
- e030356
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2952381631
- Cited by
- 41
- References
- 29
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.